|
1
|
Parkin DM and Muir CS: Cancer incidence in
five continents. Comparability and quality of data. IARC Sci Publ;
pp. 45–173. 1992
|
|
2
|
Nielsen NH, Mikkelsen F and Hansen JP:
Nasopharyngeal cancer in Greenland. The incidence in an Arctic
Eskimo population. Acta Pathol Microbiol Scand A. 85:850–858.
1977.PubMed/NCBI
|
|
3
|
DeNittis AS, Liu L, Rosenthal DI and
Machtay M: Nasopharyngeal carcinoma treated with external
radiotherapy, brachytherapy, and concurrent/adjuvant chemotherapy.
Am J Clin Oncol. 25:93–95. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanguineti G, Geara FB, Garden AS, et al:
Carcinoma of the nasopharynx treated by radiotherapy alone:
determinants of local and regional control. Int J Radiat Oncol Biol
Phys. 37:985–996. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Yen C, Liaw D, et al: PTEN, a
putative protein tyrosine phosphatase gene mutated in human brain,
breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar
|
|
6
|
Liotta LA: Tumor invasion and metastases -
role of the extracellular matrix: Rhoads Memorial Award lecture.
Cancer Res. 46:1–7. 1986.PubMed/NCBI
|
|
7
|
Leslie NR and Downes CP: PTEN function:
how normal cells control it and tumour cells lose it. Biochem J.
382:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu X, Senechal K, Neshat MS, Whang YE and
Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions
as a negative regulator of the phosphoinositide 3-kinase/Akt
pathway. Proc Natl Acad Sci USA. 95:15587–15591. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soria JC, Lee HY, Lee JI, et al: Lack of
PTEN expression in non-small cell lung cancer could be related to
promoter methylation. Clin Cancer Res. 8:1178–1184. 2002.PubMed/NCBI
|
|
10
|
Salvesen HB, MacDonald N, Ryan A, et al:
PTEN methylation is associated with advanced stage and
microsatellite instability in endometrial carcinoma. Int J Cancer.
91:22–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cairns P, Okami K, Halachmi S, et al:
Frequent inactivation of PTEN/MMAC1 in primary prostate
cancer. Cancer Res. 57:4997–5000. 1997.
|
|
12
|
Wiencke JK, Zheng S, Jelluma N, et al:
Methylation of the PTEN promoter defines low-grade gliomas
and secondary glioblastoma. Neuro Oncol. 9:271–279. 2007.
|
|
13
|
Hino R, Uozaki H, Murakami N, et al:
Activation of DNA methyltransferase 1 by EBV latent membrane
protein 2A leads to promoter hypermethylation of PTEN gene
in gastric carcinoma. Cancer Res. 69:2766–2774. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang YH, Lee HS and Kim WH: Promoter
methylation and silencing of PTEN in gastric carcinoma. Lab Invest.
82:285–291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Furuta J, Umebayashi Y, Miyamoto K, et al:
Promoter methylation profiling of 30 genes in human malignant
melanoma. Cancer Sci. 95:962–968. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Montiel-Duarte C, Cordeu L, Agirre X, et
al: Resistance to Imatinib Mesylate-induced apoptosis in acute
lymphoblastic leukemia is associated with PTEN down-regulation due
to promoter hypermethylation. Leuk Res. 32:709–716. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheung TH, Lo KW, Yim SF, et al:
Epigenetic and genetic alternation of PTEN in cervical
neoplasm. Gynecol Oncol. 93:621–627. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jones PA and Taylor SM: Cellular
differentiation, cytidine analogs and DNA methylation. Cell.
20:85–93. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Teo P, Yu P, Lee WY, et al: Significant
prognosticators after primary radiotherapy in 903 nondisseminated
nasopharyngeal carcinoma evaluated by computer tomography. Int J
Radiat Oncol Biol Phys. 36:291–304. 1996. View Article : Google Scholar
|
|
20
|
Sun Y, Hegamyer G, Cheng YJ, et al: An
infrequent point mutation of the p53 gene in human nasopharyngeal
carcinoma. Proc Natl Acad Sci USA. 89:6516–6520. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Z, Sun D, Van Do N, Tang A, Hu L and
Huang G: Inactivation of RASSF2A by promoter methylation
correlates with lymph node metastasis in nasopharyngeal carcinoma.
Int J Cancer. 120:32–38. 2007.
|
|
22
|
Mo Y, Midorikawa K, Zhang Z, et al:
Promoter hypermethylation of Ras-related GTPase gene
RRAD inactivates a tumor suppressor function in
nasopharyngeal carcinoma. Cancer Lett. 323:147–154. 2012.
|
|
23
|
Shu XS, Li L, Ji M, et al: FEZF2, a
novel 3p14 tumor suppressor gene, represses oncogene EZH2
and MDM2 expression and is frequently methylated in
nasopharyngeal carcinoma. Carcinogenesis. 34:1984–1993. 2013.
View Article : Google Scholar
|
|
24
|
Li L, Tao Q, Jin H, et al: The tumor
suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53
signaling and is frequently silenced in nasopharyngeal carcinoma.
Clin Cancer Res. 16:2949–2958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brenner W, Farber G, Herget T, Lehr HA,
Hengstler JG and Thuroff JW: Loss of tumor suppressor protein PTEN
during renal carcinogenesis. Int J Cancer. 99:53–57. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guldberg P, Thor SP, Birck A, Ahrenkiel V,
Kirkin AF and Zeuthen J: Disruption of the MMAC1/PTEN gene
by deletion or mutation is a frequent event in malignant melanoma.
Cancer Res. 57:3660–3663. 1997.PubMed/NCBI
|
|
27
|
Oda K, Stokoe D, Taketani Y and McCormick
F: High frequency of coexistent mutations of PIK3CA and
PTEN genes in endometrial carcinoma. Cancer Res.
65:10669–10673. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cairns P, Evron E, Okami K, et al: Point
mutation and homozygous deletion of PTEN/MMAC1 in primary
bladder cancers. Oncogene. 16:3215–3218. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liaw D, Marsh DJ, Li J, et al: Germline
mutations of the PTEN gene in Cowden disease, an inherited
breast and thyroid cancer syndrome. Nat Genet. 16:64–67. 1997.
|
|
30
|
Qu C, Liang Z, Huang J, et al: MiR-205
determines the radioresistance of human nasopharyngeal carcinoma by
directly targeting PTEN. Cell Cycle. 11:785–796. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mutter GL, Lin MC, Fitzgerald JT, et al:
Altered PTEN expression as a diagnostic marker for the earliest
endometrial precancers. J Natl Cancer Inst. 92:924–930. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heyn H, Carmona FJ, Gomez A, et al: DNA
methylation profiling in breast cancer discordant identical twins
identifies DOK7 as novel epigenetic biomarker.
Carcinogenesis. 34:102–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun D, Zhang Z, Van Do N, Huang G, Ernberg
I and Hu L: Aberrant methylation of CDH13 gene in nasopharyngeal
carcinoma could serve as a potential diagnostic biomarker. Oral
Oncol. 43:82–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
